| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Migraine Disorders | 127 | 2023 | 1620 | 17.220 |
Why?
|
| Migraine with Aura | 26 | 2022 | 203 | 5.350 |
Why?
|
| Stroke | 83 | 2023 | 9981 | 4.160 |
Why?
|
| Migraine without Aura | 15 | 2021 | 83 | 3.810 |
Why?
|
| Headache | 17 | 2022 | 1226 | 3.290 |
Why?
|
| Restless Legs Syndrome | 10 | 2019 | 228 | 3.070 |
Why?
|
| Cardiovascular Diseases | 56 | 2023 | 15160 | 2.770 |
Why?
|
| Brain Ischemia | 31 | 2021 | 3265 | 2.520 |
Why?
|
| Intracranial Hemorrhages | 10 | 2020 | 855 | 1.990 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 14 | 2016 | 2282 | 1.820 |
Why?
|
| Headache Disorders | 5 | 2023 | 130 | 1.740 |
Why?
|
| Aspirin | 24 | 2013 | 3283 | 1.690 |
Why?
|
| Risk Factors | 135 | 2023 | 72296 | 1.400 |
Why?
|
| Women's Health | 14 | 2023 | 2034 | 1.300 |
Why?
|
| Germany | 27 | 2023 | 862 | 1.180 |
Why?
|
| Propensity Score | 10 | 2022 | 1781 | 1.160 |
Why?
|
| Humans | 370 | 2024 | 744366 | 1.160 |
Why?
|
| Tryptamines | 7 | 2022 | 88 | 1.160 |
Why?
|
| Tension-Type Headache | 3 | 2020 | 77 | 1.130 |
Why?
|
| Cohort Studies | 83 | 2024 | 40559 | 1.130 |
Why?
|
| France | 12 | 2019 | 517 | 1.070 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 4 | 2010 | 284 | 1.020 |
Why?
|
| Genetic Predisposition to Disease | 32 | 2022 | 17446 | 1.010 |
Why?
|
| Polymorphism, Genetic | 14 | 2014 | 4328 | 1.010 |
Why?
|
| Female | 209 | 2023 | 380193 | 0.960 |
Why?
|
| Middle Aged | 168 | 2023 | 213390 | 0.930 |
Why?
|
| Peptidyl-Dipeptidase A | 3 | 2010 | 365 | 0.910 |
Why?
|
| Television | 2 | 2016 | 409 | 0.900 |
Why?
|
| Prospective Studies | 91 | 2023 | 53290 | 0.850 |
Why?
|
| Ischemic Attack, Transient | 5 | 2023 | 935 | 0.840 |
Why?
|
| Cluster Headache | 8 | 2014 | 54 | 0.840 |
Why?
|
| Respiratory Insufficiency | 9 | 2022 | 1199 | 0.820 |
Why?
|
| Risk Assessment | 37 | 2023 | 23336 | 0.800 |
Why?
|
| Berlin | 10 | 2022 | 23 | 0.770 |
Why?
|
| Male | 188 | 2023 | 350115 | 0.750 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 3 | 2014 | 322 | 0.740 |
Why?
|
| Prevalence | 33 | 2023 | 15221 | 0.740 |
Why?
|
| Population Surveillance | 4 | 2018 | 2616 | 0.740 |
Why?
|
| Vitamin E | 8 | 2012 | 869 | 0.730 |
Why?
|
| Aged | 126 | 2023 | 163288 | 0.730 |
Why?
|
| Cognition Disorders | 9 | 2015 | 4043 | 0.720 |
Why?
|
| Randomized Controlled Trials as Topic | 31 | 2023 | 9955 | 0.710 |
Why?
|
| Positive-Pressure Respiration | 5 | 2018 | 633 | 0.710 |
Why?
|
| Thoracic Injuries | 1 | 2022 | 272 | 0.710 |
Why?
|
| Smoking | 19 | 2020 | 8987 | 0.690 |
Why?
|
| Polymorphism, Single Nucleotide | 22 | 2022 | 15520 | 0.690 |
Why?
|
| Fatty Acids, Omega-3 | 2 | 2021 | 1344 | 0.680 |
Why?
|
| Vascular System Injuries | 1 | 2022 | 250 | 0.660 |
Why?
|
| Recovery of Function | 5 | 2017 | 2926 | 0.650 |
Why?
|
| Comorbidity | 28 | 2019 | 10388 | 0.650 |
Why?
|
| Sinus Thrombosis, Intracranial | 1 | 2019 | 103 | 0.630 |
Why?
|
| Hyperlipidemias | 4 | 2020 | 789 | 0.630 |
Why?
|
| Coronavirus | 1 | 2020 | 158 | 0.620 |
Why?
|
| Body Mass Index | 23 | 2019 | 12721 | 0.620 |
Why?
|
| Cerebral Veins | 1 | 2019 | 156 | 0.610 |
Why?
|
| Causality | 8 | 2023 | 1275 | 0.610 |
Why?
|
| Genome-Wide Association Study | 17 | 2022 | 12262 | 0.600 |
Why?
|
| Authorship | 1 | 2020 | 271 | 0.600 |
Why?
|
| Risk | 25 | 2020 | 9688 | 0.600 |
Why?
|
| Schools | 5 | 2021 | 1433 | 0.600 |
Why?
|
| Tissue Plasminogen Activator | 4 | 2021 | 1261 | 0.600 |
Why?
|
| Analgesics | 5 | 2022 | 1040 | 0.600 |
Why?
|
| Tuna | 1 | 2016 | 19 | 0.580 |
Why?
|
| Dental Caries | 1 | 2020 | 415 | 0.570 |
Why?
|
| Proportional Hazards Models | 31 | 2021 | 12356 | 0.560 |
Why?
|
| Incidence | 35 | 2023 | 20952 | 0.560 |
Why?
|
| Obesity | 12 | 2020 | 12746 | 0.560 |
Why?
|
| Aged, 80 and over | 58 | 2022 | 57776 | 0.550 |
Why?
|
| Cross-Sectional Studies | 25 | 2022 | 25039 | 0.550 |
Why?
|
| Medical Records | 3 | 2020 | 1413 | 0.540 |
Why?
|
| Seafood | 2 | 2016 | 384 | 0.540 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2022 | 795 | 0.530 |
Why?
|
| Pain Measurement | 2 | 2020 | 3420 | 0.530 |
Why?
|
| Students | 4 | 2021 | 1647 | 0.520 |
Why?
|
| Dementia | 7 | 2015 | 2518 | 0.520 |
Why?
|
| Myocardial Revascularization | 3 | 2016 | 841 | 0.520 |
Why?
|
| Alcohol Drinking | 7 | 2016 | 3966 | 0.510 |
Why?
|
| Vascular Diseases | 3 | 2016 | 1161 | 0.500 |
Why?
|
| Cerebrovascular Disorders | 4 | 2019 | 1504 | 0.500 |
Why?
|
| Parkinson Disease | 6 | 2013 | 2775 | 0.500 |
Why?
|
| National Health Programs | 2 | 2017 | 445 | 0.500 |
Why?
|
| Logistic Models | 26 | 2023 | 13409 | 0.490 |
Why?
|
| Computers, Handheld | 1 | 2016 | 208 | 0.480 |
Why?
|
| Health Status Indicators | 3 | 2017 | 970 | 0.480 |
Why?
|
| Follow-Up Studies | 41 | 2021 | 39052 | 0.480 |
Why?
|
| Coronary Disease | 6 | 2012 | 6077 | 0.480 |
Why?
|
| Kidney Diseases | 7 | 2011 | 2148 | 0.470 |
Why?
|
| Age Distribution | 10 | 2016 | 2902 | 0.470 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 3135 | 0.470 |
Why?
|
| Bariatric Surgery | 1 | 2023 | 952 | 0.470 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 3242 | 0.470 |
Why?
|
| Adult | 99 | 2023 | 214052 | 0.460 |
Why?
|
| Myocardial Infarction | 15 | 2015 | 11718 | 0.460 |
Why?
|
| Tinnitus | 1 | 2016 | 195 | 0.460 |
Why?
|
| Cerebral Hemorrhage | 7 | 2021 | 2647 | 0.460 |
Why?
|
| Esophageal Neoplasms | 1 | 2023 | 1585 | 0.460 |
Why?
|
| Confidence Intervals | 13 | 2021 | 2971 | 0.450 |
Why?
|
| Hypertension | 12 | 2021 | 8479 | 0.450 |
Why?
|
| Computers | 1 | 2016 | 612 | 0.450 |
Why?
|
| Blood Vessels | 2 | 2010 | 1125 | 0.450 |
Why?
|
| Resuscitation | 1 | 2018 | 658 | 0.450 |
Why?
|
| Life Style | 8 | 2021 | 3835 | 0.440 |
Why?
|
| Odds Ratio | 23 | 2016 | 9849 | 0.440 |
Why?
|
| Lipids | 5 | 2020 | 3307 | 0.440 |
Why?
|
| Case-Control Studies | 36 | 2022 | 21748 | 0.430 |
Why?
|
| Obesity, Morbid | 1 | 2023 | 1213 | 0.430 |
Why?
|
| Hospital Mortality | 11 | 2018 | 5316 | 0.430 |
Why?
|
| Men's Health | 1 | 2012 | 73 | 0.420 |
Why?
|
| Mortality | 3 | 2020 | 2864 | 0.420 |
Why?
|
| Statistics as Topic | 2 | 2016 | 2373 | 0.410 |
Why?
|
| Pandemics | 8 | 2023 | 8385 | 0.410 |
Why?
|
| Cardiology | 1 | 2023 | 1668 | 0.410 |
Why?
|
| Genetic Loci | 5 | 2022 | 2575 | 0.410 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 2 | 2018 | 3658 | 0.410 |
Why?
|
| Leukoencephalopathies | 1 | 2014 | 238 | 0.410 |
Why?
|
| Brain Diseases | 6 | 2018 | 1563 | 0.400 |
Why?
|
| Neuropsychological Tests | 7 | 2023 | 6994 | 0.400 |
Why?
|
| Lymphotoxin-alpha | 1 | 2011 | 98 | 0.400 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2022 | 1354 | 0.400 |
Why?
|
| Coffee | 2 | 2018 | 578 | 0.390 |
Why?
|
| Fibromyalgia | 1 | 2015 | 388 | 0.380 |
Why?
|
| Health Services Research | 2 | 2020 | 1836 | 0.380 |
Why?
|
| Intensive Care Units | 7 | 2018 | 3680 | 0.370 |
Why?
|
| Parkinson Disease, Secondary | 1 | 2011 | 126 | 0.370 |
Why?
|
| Double-Blind Method | 17 | 2021 | 12025 | 0.370 |
Why?
|
| Intraoperative Care | 4 | 2018 | 767 | 0.370 |
Why?
|
| Age Factors | 23 | 2021 | 18373 | 0.370 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2013 | 550 | 0.360 |
Why?
|
| Fibrinolytic Agents | 4 | 2009 | 2158 | 0.360 |
Why?
|
| Biomedical Research | 3 | 2020 | 3309 | 0.360 |
Why?
|
| Food Supply | 1 | 2015 | 524 | 0.360 |
Why?
|
| Self Concept | 1 | 2016 | 1025 | 0.360 |
Why?
|
| Public Health | 3 | 2018 | 2602 | 0.350 |
Why?
|
| Cooking | 1 | 2012 | 313 | 0.350 |
Why?
|
| United States | 48 | 2023 | 69872 | 0.350 |
Why?
|
| Exercise | 4 | 2016 | 5615 | 0.340 |
Why?
|
| Proton Pump Inhibitors | 1 | 2014 | 526 | 0.340 |
Why?
|
| Receptors, Neuropeptide | 4 | 2015 | 111 | 0.340 |
Why?
|
| Respiration Disorders | 3 | 2017 | 371 | 0.330 |
Why?
|
| Prostatic Neoplasms | 17 | 2023 | 11126 | 0.330 |
Why?
|
| Endovascular Procedures | 1 | 2022 | 1980 | 0.330 |
Why?
|
| Motor Activity | 4 | 2011 | 2715 | 0.320 |
Why?
|
| Cerebral Infarction | 3 | 2011 | 1011 | 0.320 |
Why?
|
| Critical Illness | 4 | 2016 | 2670 | 0.320 |
Why?
|
| Adiposity | 1 | 2018 | 1806 | 0.320 |
Why?
|
| Sex Characteristics | 3 | 2020 | 2585 | 0.320 |
Why?
|
| Registries | 16 | 2022 | 8091 | 0.320 |
Why?
|
| Vitamins | 4 | 2012 | 1623 | 0.320 |
Why?
|
| Postoperative Complications | 12 | 2021 | 15297 | 0.320 |
Why?
|
| Sex Distribution | 6 | 2016 | 2297 | 0.320 |
Why?
|
| Angiotensinogen | 1 | 2008 | 163 | 0.320 |
Why?
|
| Anesthesiology | 1 | 2018 | 1060 | 0.310 |
Why?
|
| Prognosis | 21 | 2021 | 29060 | 0.310 |
Why?
|
| Adiponectin | 4 | 2015 | 1101 | 0.310 |
Why?
|
| Nuts | 1 | 2010 | 257 | 0.310 |
Why?
|
| Principal Component Analysis | 1 | 2011 | 940 | 0.310 |
Why?
|
| Sex Factors | 16 | 2022 | 10400 | 0.310 |
Why?
|
| Blood Pressure | 6 | 2020 | 8551 | 0.310 |
Why?
|
| Angina Pectoris | 1 | 2012 | 977 | 0.310 |
Why?
|
| Databases as Topic | 1 | 2009 | 475 | 0.300 |
Why?
|
| Cholesterol | 8 | 2012 | 2919 | 0.300 |
Why?
|
| Acetaminophen | 3 | 2006 | 545 | 0.300 |
Why?
|
| Contraceptives, Oral, Hormonal | 2 | 2020 | 188 | 0.300 |
Why?
|
| Telomere | 1 | 2013 | 910 | 0.300 |
Why?
|
| Feeding Behavior | 2 | 2010 | 3188 | 0.300 |
Why?
|
| Suicide, Attempted | 1 | 2015 | 1218 | 0.300 |
Why?
|
| Abnormalities, Drug-Induced | 1 | 2010 | 317 | 0.300 |
Why?
|
| Brain Infarction | 1 | 2009 | 299 | 0.290 |
Why?
|
| Vitamin D | 1 | 2021 | 3224 | 0.290 |
Why?
|
| Aging | 6 | 2011 | 8664 | 0.290 |
Why?
|
| Models, Theoretical | 2 | 2009 | 3589 | 0.290 |
Why?
|
| Ascorbic Acid | 4 | 2012 | 651 | 0.280 |
Why?
|
| Length of Stay | 5 | 2018 | 6311 | 0.280 |
Why?
|
| Societies, Medical | 2 | 2018 | 3743 | 0.280 |
Why?
|
| Depression | 7 | 2022 | 7759 | 0.280 |
Why?
|
| Suicidal Ideation | 1 | 2015 | 1246 | 0.280 |
Why?
|
| Cyclooxygenase Inhibitors | 2 | 2006 | 371 | 0.280 |
Why?
|
| Mutagenesis, Insertional | 1 | 2009 | 655 | 0.270 |
Why?
|
| Triglycerides | 5 | 2019 | 2453 | 0.270 |
Why?
|
| Algorithms | 6 | 2022 | 13882 | 0.270 |
Why?
|
| Estrogen Receptor alpha | 1 | 2010 | 577 | 0.270 |
Why?
|
| Quality of Life | 8 | 2023 | 12802 | 0.270 |
Why?
|
| Receptors, Androgen | 2 | 2010 | 1058 | 0.270 |
Why?
|
| Leptin | 4 | 2015 | 1600 | 0.270 |
Why?
|
| Data Interpretation, Statistical | 4 | 2010 | 2716 | 0.270 |
Why?
|
| Epilepsy | 3 | 2013 | 3310 | 0.270 |
Why?
|
| beta Carotene | 8 | 2010 | 527 | 0.270 |
Why?
|
| Sickness Impact Profile | 1 | 2007 | 302 | 0.270 |
Why?
|
| Analgesics, Non-Narcotic | 2 | 2006 | 366 | 0.260 |
Why?
|
| Intubation, Intratracheal | 6 | 2018 | 1364 | 0.260 |
Why?
|
| Receptors, Progesterone | 1 | 2010 | 1098 | 0.260 |
Why?
|
| Genotype | 16 | 2021 | 12952 | 0.260 |
Why?
|
| Neuromuscular Blocking Agents | 3 | 2016 | 130 | 0.260 |
Why?
|
| Dyspepsia | 1 | 2006 | 116 | 0.250 |
Why?
|
| Diet, Mediterranean | 1 | 2012 | 700 | 0.250 |
Why?
|
| Physicians | 16 | 2012 | 4567 | 0.250 |
Why?
|
| Educational Status | 4 | 2023 | 2540 | 0.250 |
Why?
|
| Diabetes Complications | 4 | 2020 | 1359 | 0.250 |
Why?
|
| Thrombolytic Therapy | 3 | 2023 | 2162 | 0.250 |
Why?
|
| Models, Statistical | 5 | 2021 | 5101 | 0.250 |
Why?
|
| Antioxidants | 5 | 2011 | 1659 | 0.250 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 2024 | 2232 | 0.240 |
Why?
|
| Neoplasms | 11 | 2012 | 21696 | 0.240 |
Why?
|
| Cognition | 3 | 2023 | 6770 | 0.240 |
Why?
|
| Sequence Deletion | 1 | 2009 | 1525 | 0.240 |
Why?
|
| Neurology | 1 | 2012 | 763 | 0.240 |
Why?
|
| Benzodiazepines | 3 | 2015 | 1101 | 0.240 |
Why?
|
| Renin-Angiotensin System | 1 | 2008 | 758 | 0.230 |
Why?
|
| Heart Arrest | 4 | 2021 | 1470 | 0.230 |
Why?
|
| Young Adult | 21 | 2022 | 56429 | 0.230 |
Why?
|
| Cerebral Arteries | 4 | 2010 | 494 | 0.230 |
Why?
|
| Therapeutics | 1 | 2004 | 116 | 0.230 |
Why?
|
| Common Cold | 1 | 2003 | 61 | 0.230 |
Why?
|
| International Classification of Diseases | 1 | 2009 | 867 | 0.230 |
Why?
|
| Severity of Illness Index | 7 | 2016 | 15535 | 0.230 |
Why?
|
| Electronic Health Records | 1 | 2020 | 4468 | 0.230 |
Why?
|
| Health Resources | 1 | 2009 | 911 | 0.220 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2008 | 536 | 0.220 |
Why?
|
| Adolescent | 25 | 2022 | 85779 | 0.220 |
Why?
|
| Delirium | 1 | 2014 | 1610 | 0.220 |
Why?
|
| Genetic Markers | 4 | 2016 | 2634 | 0.220 |
Why?
|
| Chickenpox | 1 | 2023 | 131 | 0.220 |
Why?
|
| Research Design | 8 | 2022 | 5984 | 0.220 |
Why?
|
| Nonprescription Drugs | 1 | 2003 | 116 | 0.220 |
Why?
|
| Income | 1 | 2011 | 1913 | 0.220 |
Why?
|
| Diet | 4 | 2014 | 7937 | 0.210 |
Why?
|
| Inpatients | 2 | 2021 | 2518 | 0.210 |
Why?
|
| Predictive Value of Tests | 11 | 2016 | 15078 | 0.210 |
Why?
|
| Serotonin 5-HT1 Receptor Agonists | 2 | 2016 | 43 | 0.210 |
Why?
|
| Probability | 4 | 2023 | 2506 | 0.210 |
Why?
|
| Weight Gain | 1 | 2012 | 2293 | 0.210 |
Why?
|
| Chronic Disease | 8 | 2020 | 9145 | 0.210 |
Why?
|
| Quality Indicators, Health Care | 1 | 2012 | 1831 | 0.200 |
Why?
|
| Research Support as Topic | 1 | 2006 | 705 | 0.200 |
Why?
|
| Glomerular Filtration Rate | 9 | 2011 | 2166 | 0.200 |
Why?
|
| Editorial Policies | 1 | 2006 | 451 | 0.200 |
Why?
|
| Conflict of Interest | 1 | 2006 | 544 | 0.200 |
Why?
|
| Italy | 2 | 2020 | 832 | 0.200 |
Why?
|
| Treatment Outcome | 23 | 2023 | 63107 | 0.200 |
Why?
|
| Hospitals | 3 | 2023 | 3954 | 0.200 |
Why?
|
| Gene Frequency | 5 | 2011 | 3587 | 0.200 |
Why?
|
| Erectile Dysfunction | 2 | 2023 | 461 | 0.200 |
Why?
|
| Pneumonia | 4 | 2023 | 2133 | 0.200 |
Why?
|
| Cerebrovascular Circulation | 2 | 2011 | 2732 | 0.190 |
Why?
|
| Dental Caries Susceptibility | 1 | 2020 | 25 | 0.190 |
Why?
|
| Critical Care | 4 | 2020 | 2647 | 0.190 |
Why?
|
| Longitudinal Studies | 11 | 2022 | 13991 | 0.190 |
Why?
|
| Carcinoma | 1 | 2012 | 2375 | 0.190 |
Why?
|
| Diabetes Mellitus, Type 2 | 4 | 2019 | 11726 | 0.190 |
Why?
|
| Reproducibility of Results | 10 | 2020 | 19905 | 0.190 |
Why?
|
| Contraceptives, Oral, Combined | 2 | 2018 | 113 | 0.190 |
Why?
|
| Urinary Incontinence | 2 | 2023 | 496 | 0.190 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2011 | 4424 | 0.190 |
Why?
|
| Continuous Positive Airway Pressure | 2 | 2015 | 546 | 0.190 |
Why?
|
| Cholesterol, LDL | 4 | 2019 | 2355 | 0.180 |
Why?
|
| Intracranial Thrombosis | 1 | 2021 | 113 | 0.180 |
Why?
|
| Brain | 7 | 2016 | 26388 | 0.180 |
Why?
|
| Multivariate Analysis | 12 | 2012 | 12244 | 0.180 |
Why?
|
| Cough | 1 | 2003 | 555 | 0.180 |
Why?
|
| Insecticides | 1 | 2021 | 195 | 0.180 |
Why?
|
| Vasopressins | 1 | 2021 | 370 | 0.180 |
Why?
|
| Methylprednisolone | 1 | 2021 | 387 | 0.180 |
Why?
|
| Myocardial Ischemia | 2 | 2008 | 2148 | 0.180 |
Why?
|
| Physical Fitness | 2 | 2019 | 732 | 0.180 |
Why?
|
| Pulmonary Edema | 3 | 2018 | 414 | 0.180 |
Why?
|
| Continuity of Patient Care | 3 | 2021 | 1049 | 0.180 |
Why?
|
| Wounds and Injuries | 2 | 2014 | 2400 | 0.180 |
Why?
|
| Sleep Apnea, Obstructive | 3 | 2018 | 1813 | 0.180 |
Why?
|
| Stress, Psychological | 1 | 2014 | 4245 | 0.170 |
Why?
|
| Neostigmine | 3 | 2015 | 69 | 0.170 |
Why?
|
| Renal Dialysis | 1 | 2008 | 1783 | 0.170 |
Why?
|
| C-Reactive Protein | 6 | 2012 | 3778 | 0.170 |
Why?
|
| Subarachnoid Hemorrhage | 2 | 2003 | 1018 | 0.170 |
Why?
|
| Health Behavior | 3 | 2008 | 2635 | 0.160 |
Why?
|
| Pneumococcal Infections | 1 | 2023 | 497 | 0.160 |
Why?
|
| Technology Assessment, Biomedical | 1 | 2021 | 306 | 0.160 |
Why?
|
| Health Status | 3 | 2010 | 4034 | 0.160 |
Why?
|
| Polymerase Chain Reaction | 5 | 2013 | 6171 | 0.160 |
Why?
|
| Regression Analysis | 4 | 2022 | 6459 | 0.160 |
Why?
|
| Hemostasis | 1 | 2021 | 458 | 0.160 |
Why?
|
| Rehydration Solutions | 1 | 2018 | 47 | 0.160 |
Why?
|
| Dental Care | 1 | 2020 | 262 | 0.160 |
Why?
|
| Defibrillators | 1 | 2018 | 37 | 0.160 |
Why?
|
| Respiration, Artificial | 3 | 2018 | 2569 | 0.150 |
Why?
|
| Cholesterol, HDL | 5 | 2019 | 1813 | 0.150 |
Why?
|
| Cardiovascular Agents | 2 | 2021 | 850 | 0.150 |
Why?
|
| Sumatriptan | 2 | 2016 | 65 | 0.150 |
Why?
|
| Communicable Disease Control | 2 | 2021 | 856 | 0.150 |
Why?
|
| Receptors, Adrenergic, beta-2 | 2 | 2009 | 201 | 0.150 |
Why?
|
| Amyotrophic Lateral Sclerosis | 2 | 2018 | 1414 | 0.150 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 2 | 2010 | 134 | 0.150 |
Why?
|
| Social Class | 1 | 2006 | 1997 | 0.150 |
Why?
|
| Atherosclerosis | 2 | 2014 | 3444 | 0.150 |
Why?
|
| Patient Participation | 1 | 2007 | 1457 | 0.150 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2010 | 2408 | 0.150 |
Why?
|
| Internet | 1 | 2009 | 3056 | 0.150 |
Why?
|
| Surgical Procedures, Operative | 2 | 2021 | 1877 | 0.150 |
Why?
|
| Child | 17 | 2023 | 77709 | 0.150 |
Why?
|
| Comparative Effectiveness Research | 1 | 2022 | 680 | 0.150 |
Why?
|
| Interdisciplinary Communication | 2 | 2017 | 950 | 0.150 |
Why?
|
| Perception | 2 | 2021 | 1198 | 0.150 |
Why?
|
| Epinephrine | 2 | 2021 | 792 | 0.150 |
Why?
|
| Substance-Related Disorders | 1 | 2013 | 4257 | 0.150 |
Why?
|
| Tea | 1 | 2018 | 275 | 0.150 |
Why?
|
| Waist-Hip Ratio | 2 | 2008 | 517 | 0.140 |
Why?
|
| Anti-HIV Agents | 2 | 2024 | 4255 | 0.140 |
Why?
|
| Early Ambulation | 1 | 2016 | 44 | 0.140 |
Why?
|
| Placebos | 4 | 2021 | 1676 | 0.140 |
Why?
|
| Progestins | 1 | 2018 | 306 | 0.140 |
Why?
|
| Family Characteristics | 1 | 2021 | 1000 | 0.140 |
Why?
|
| Foramen Ovale, Patent | 2 | 2010 | 223 | 0.140 |
Why?
|
| Survival Analysis | 8 | 2017 | 10252 | 0.140 |
Why?
|
| Checklist | 1 | 2023 | 833 | 0.140 |
Why?
|
| Epidemiologic Methods | 3 | 2011 | 1364 | 0.140 |
Why?
|
| Aorta, Thoracic | 1 | 2022 | 1084 | 0.140 |
Why?
|
| Contraceptives, Oral | 2 | 2009 | 564 | 0.140 |
Why?
|
| Pregnancy Complications | 1 | 2010 | 2861 | 0.130 |
Why?
|
| Ketorolac | 1 | 2016 | 79 | 0.130 |
Why?
|
| Hyperoxia | 1 | 2018 | 262 | 0.130 |
Why?
|
| alpha-Tocopherol | 3 | 2011 | 127 | 0.130 |
Why?
|
| Hypercholesterolemia | 4 | 2015 | 1151 | 0.130 |
Why?
|
| Iran | 1 | 2018 | 710 | 0.130 |
Why?
|
| Quadriceps Muscle | 1 | 2016 | 144 | 0.130 |
Why?
|
| Health Surveys | 6 | 2019 | 4036 | 0.130 |
Why?
|
| Heart Diseases | 1 | 2008 | 2789 | 0.130 |
Why?
|
| Time Factors | 14 | 2020 | 40075 | 0.130 |
Why?
|
| Meta-Analysis as Topic | 1 | 2020 | 1342 | 0.130 |
Why?
|
| Oral Health | 1 | 2020 | 474 | 0.130 |
Why?
|
| Periodicals as Topic | 1 | 2006 | 1431 | 0.130 |
Why?
|
| Self Report | 4 | 2019 | 3553 | 0.130 |
Why?
|
| Mass Screening | 2 | 2010 | 5253 | 0.130 |
Why?
|
| Extracellular Matrix Proteins | 2 | 2011 | 850 | 0.130 |
Why?
|
| Dietary Supplements | 5 | 2012 | 3296 | 0.130 |
Why?
|
| Rare Diseases | 1 | 2020 | 553 | 0.130 |
Why?
|
| Models, Cardiovascular | 1 | 2020 | 996 | 0.120 |
Why?
|
| Tidal Volume | 4 | 2018 | 490 | 0.120 |
Why?
|
| Climate | 2 | 2023 | 147 | 0.120 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2010 | 2917 | 0.120 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2016 | 346 | 0.120 |
Why?
|
| Genetic Pleiotropy | 1 | 2015 | 182 | 0.120 |
Why?
|
| HIV Infections | 5 | 2024 | 16715 | 0.120 |
Why?
|
| Myogenic Regulatory Factors | 2 | 2011 | 106 | 0.120 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2017 | 367 | 0.120 |
Why?
|
| Telemedicine | 2 | 2022 | 2872 | 0.120 |
Why?
|
| Ultrasonography, Interventional | 1 | 2022 | 1486 | 0.120 |
Why?
|
| Caffeine | 1 | 2018 | 699 | 0.120 |
Why?
|
| Fluid Therapy | 1 | 2018 | 593 | 0.120 |
Why?
|
| Heart Septal Defects, Atrial | 2 | 2007 | 478 | 0.120 |
Why?
|
| Menarche | 1 | 2016 | 516 | 0.120 |
Why?
|
| Glycoproteins | 3 | 2011 | 2266 | 0.120 |
Why?
|
| Mandatory Programs | 1 | 2014 | 87 | 0.120 |
Why?
|
| Disease Progression | 6 | 2015 | 13286 | 0.120 |
Why?
|
| Brain Neoplasms | 1 | 2015 | 8861 | 0.110 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2011 | 4266 | 0.110 |
Why?
|
| Alzheimer Disease | 3 | 2014 | 8038 | 0.110 |
Why?
|
| Phenotype | 6 | 2021 | 16367 | 0.110 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 1 | 2018 | 339 | 0.110 |
Why?
|
| Patient Readmission | 2 | 2018 | 3116 | 0.110 |
Why?
|
| Kidney Transplantation | 1 | 2008 | 4251 | 0.110 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2017 | 484 | 0.110 |
Why?
|
| Anesthesia, General | 2 | 2018 | 1171 | 0.110 |
Why?
|
| Publishing | 1 | 2020 | 833 | 0.110 |
Why?
|
| Genetic Association Studies | 2 | 2014 | 2703 | 0.110 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2015 | 35425 | 0.110 |
Why?
|
| Atropine | 1 | 2013 | 244 | 0.110 |
Why?
|
| Airway Obstruction | 1 | 2018 | 664 | 0.110 |
Why?
|
| Physical Therapy Modalities | 1 | 2016 | 550 | 0.110 |
Why?
|
| Hematoma, Subdural | 1 | 2013 | 126 | 0.100 |
Why?
|
| Asthma | 2 | 2008 | 6010 | 0.100 |
Why?
|
| Glucocorticoids | 1 | 2021 | 2108 | 0.100 |
Why?
|
| Risk Reduction Behavior | 2 | 2011 | 1125 | 0.100 |
Why?
|
| Postmenopause | 1 | 2021 | 2460 | 0.100 |
Why?
|
| Venous Thrombosis | 1 | 2021 | 1239 | 0.100 |
Why?
|
| Craniotomy | 1 | 2016 | 729 | 0.100 |
Why?
|
| Consensus | 2 | 2018 | 2960 | 0.100 |
Why?
|
| Frail Elderly | 1 | 2016 | 693 | 0.100 |
Why?
|
| Neuromuscular Nondepolarizing Agents | 1 | 2012 | 146 | 0.100 |
Why?
|
| Malaria | 1 | 2021 | 1239 | 0.100 |
Why?
|
| Phosphoproteins | 2 | 2011 | 2441 | 0.100 |
Why?
|
| Sarcopenia | 1 | 2016 | 368 | 0.100 |
Why?
|
| Anesthetics, Inhalation | 1 | 2017 | 570 | 0.100 |
Why?
|
| Receptors, G-Protein-Coupled | 3 | 2007 | 1222 | 0.100 |
Why?
|
| Estrogens | 1 | 2018 | 1566 | 0.100 |
Why?
|
| Europe | 3 | 2018 | 3338 | 0.100 |
Why?
|
| Creatinine | 6 | 2008 | 1919 | 0.100 |
Why?
|
| Thrombectomy | 1 | 2016 | 680 | 0.100 |
Why?
|
| Bradycardia | 1 | 2013 | 307 | 0.100 |
Why?
|
| Massachusetts | 7 | 2021 | 8662 | 0.100 |
Why?
|
| Patient Discharge | 3 | 2023 | 3318 | 0.100 |
Why?
|
| Patient Care Planning | 1 | 2016 | 921 | 0.100 |
Why?
|
| Serotonin Receptor Agonists | 2 | 2009 | 152 | 0.100 |
Why?
|
| Disabled Persons | 1 | 2020 | 1212 | 0.090 |
Why?
|
| Hospitalization | 6 | 2023 | 10259 | 0.090 |
Why?
|
| Neurodegenerative Diseases | 1 | 2020 | 1061 | 0.090 |
Why?
|
| Universities | 1 | 2016 | 951 | 0.090 |
Why?
|
| Racemases and Epimerases | 1 | 2011 | 113 | 0.090 |
Why?
|
| Chromosomes, Human, X | 1 | 2012 | 296 | 0.090 |
Why?
|
| Survivors | 1 | 2021 | 2291 | 0.090 |
Why?
|
| Retrospective Studies | 15 | 2022 | 77460 | 0.090 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2014 | 711 | 0.090 |
Why?
|
| Hypolipidemic Agents | 1 | 2015 | 604 | 0.090 |
Why?
|
| Receptors, FSH | 1 | 2010 | 29 | 0.090 |
Why?
|
| Diet Surveys | 1 | 2014 | 1173 | 0.090 |
Why?
|
| Oxygen | 3 | 2018 | 4189 | 0.090 |
Why?
|
| Chemoprevention | 1 | 2012 | 319 | 0.090 |
Why?
|
| Colorectal Neoplasms | 2 | 2007 | 6773 | 0.090 |
Why?
|
| Abdomen | 1 | 2016 | 1118 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 2011 | 326 | 0.090 |
Why?
|
| Psychological Tests | 1 | 2012 | 651 | 0.090 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2018 | 980 | 0.090 |
Why?
|
| Dichlorodiphenyl Dichloroethylene | 1 | 2010 | 88 | 0.090 |
Why?
|
| Overweight | 3 | 2012 | 2371 | 0.090 |
Why?
|
| Psychotropic Drugs | 1 | 2015 | 894 | 0.090 |
Why?
|
| Aromatase | 1 | 2010 | 147 | 0.090 |
Why?
|
| Nervous System Diseases | 1 | 2020 | 1622 | 0.090 |
Why?
|
| Inflammation | 1 | 2009 | 10637 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2011 | 462 | 0.090 |
Why?
|
| Aspartic Acid Endopeptidases | 1 | 2011 | 311 | 0.090 |
Why?
|
| Validation Studies as Topic | 1 | 2009 | 159 | 0.090 |
Why?
|
| Organ Size | 1 | 2014 | 2251 | 0.090 |
Why?
|
| Fishes | 1 | 2012 | 569 | 0.090 |
Why?
|
| Trichomonas Infections | 1 | 2009 | 43 | 0.090 |
Why?
|
| Activities of Daily Living | 1 | 2018 | 2419 | 0.090 |
Why?
|
| Estrogen Receptor beta | 1 | 2010 | 175 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2020 | 6539 | 0.080 |
Why?
|
| Women | 1 | 2011 | 230 | 0.080 |
Why?
|
| Trichomonas vaginalis | 1 | 2009 | 76 | 0.080 |
Why?
|
| Muscle Cells | 1 | 2010 | 197 | 0.080 |
Why?
|
| Patient Selection | 5 | 2016 | 4216 | 0.080 |
Why?
|
| Anxiety | 2 | 2022 | 4293 | 0.080 |
Why?
|
| Norway | 1 | 2010 | 448 | 0.080 |
Why?
|
| Joints | 1 | 2010 | 327 | 0.080 |
Why?
|
| Hyperacusis | 1 | 2009 | 31 | 0.080 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2004 | 3712 | 0.080 |
Why?
|
| Alleles | 3 | 2022 | 6933 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2011 | 658 | 0.080 |
Why?
|
| Breast Neoplasms | 2 | 2014 | 20824 | 0.080 |
Why?
|
| Cause of Death | 3 | 2015 | 3582 | 0.080 |
Why?
|
| Myoblasts | 1 | 2010 | 238 | 0.080 |
Why?
|
| Photophobia | 1 | 2009 | 67 | 0.080 |
Why?
|
| Endoribonucleases | 1 | 2010 | 229 | 0.080 |
Why?
|
| Forecasting | 1 | 2017 | 2951 | 0.080 |
Why?
|
| Selenoproteins | 1 | 2010 | 216 | 0.080 |
Why?
|
| Mesenchymal Stem Cells | 2 | 2010 | 1632 | 0.080 |
Why?
|
| C-Peptide | 1 | 2010 | 419 | 0.080 |
Why?
|
| Antibodies, Protozoan | 1 | 2009 | 253 | 0.080 |
Why?
|
| Pain, Postoperative | 1 | 2018 | 1643 | 0.080 |
Why?
|
| Residence Characteristics | 1 | 2018 | 2050 | 0.080 |
Why?
|
| Muscle Development | 1 | 2010 | 271 | 0.080 |
Why?
|
| Cystatins | 1 | 2007 | 55 | 0.080 |
Why?
|
| Oleic Acid | 1 | 2008 | 85 | 0.080 |
Why?
|
| Abdominal Fat | 1 | 2009 | 223 | 0.080 |
Why?
|
| Platinum Compounds | 1 | 2008 | 96 | 0.080 |
Why?
|
| Polychlorinated Biphenyls | 1 | 2010 | 245 | 0.080 |
Why?
|
| Kidney | 1 | 2003 | 7184 | 0.080 |
Why?
|
| Dermatomycoses | 1 | 2007 | 45 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2009 | 437 | 0.080 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2011 | 584 | 0.070 |
Why?
|
| Nonlinear Dynamics | 1 | 2010 | 502 | 0.070 |
Why?
|
| Onychomycosis | 1 | 2007 | 47 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2009 | 460 | 0.070 |
Why?
|
| Adipokines | 1 | 2009 | 320 | 0.070 |
Why?
|
| Selenium | 1 | 2010 | 405 | 0.070 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2024 | 2560 | 0.070 |
Why?
|
| Watchful Waiting | 1 | 2011 | 492 | 0.070 |
Why?
|
| Chicago | 1 | 2007 | 240 | 0.070 |
Why?
|
| Health Care Costs | 2 | 2011 | 3208 | 0.070 |
Why?
|
| Matched-Pair Analysis | 1 | 2007 | 288 | 0.070 |
Why?
|
| Insurance, Physician Services | 1 | 2006 | 24 | 0.070 |
Why?
|
| Heterotrimeric GTP-Binding Proteins | 1 | 2007 | 93 | 0.070 |
Why?
|
| CADASIL | 1 | 2007 | 84 | 0.070 |
Why?
|
| Primary Health Care | 1 | 2023 | 4557 | 0.070 |
Why?
|
| Linoleic Acid | 1 | 2008 | 157 | 0.070 |
Why?
|
| Injections, Intravenous | 1 | 2009 | 1420 | 0.070 |
Why?
|
| Anesthesia | 1 | 2018 | 1561 | 0.070 |
Why?
|
| Receptors, Prostaglandin E | 1 | 2006 | 56 | 0.070 |
Why?
|
| Epidemiologic Studies | 2 | 2007 | 676 | 0.070 |
Why?
|
| Brain Chemistry | 1 | 2010 | 982 | 0.070 |
Why?
|
| Glucose | 1 | 2018 | 4398 | 0.070 |
Why?
|
| Insurance Claim Reporting | 1 | 2006 | 163 | 0.070 |
Why?
|
| Pregnancy Trimester, First | 1 | 2010 | 853 | 0.070 |
Why?
|
| Nausea | 1 | 2009 | 674 | 0.070 |
Why?
|
| Blood Circulation | 2 | 2017 | 251 | 0.070 |
Why?
|
| DNA Mutational Analysis | 3 | 2009 | 4185 | 0.070 |
Why?
|
| Observation | 1 | 2007 | 312 | 0.070 |
Why?
|
| Sensitivity and Specificity | 3 | 2016 | 14723 | 0.070 |
Why?
|
| Cost-Benefit Analysis | 3 | 2023 | 5388 | 0.070 |
Why?
|
| Vomiting | 1 | 2009 | 637 | 0.070 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2006 | 329 | 0.070 |
Why?
|
| Pain | 1 | 2021 | 4988 | 0.070 |
Why?
|
| Drug Administration Schedule | 2 | 2011 | 4933 | 0.070 |
Why?
|
| Mental Disorders | 2 | 2018 | 6598 | 0.060 |
Why?
|
| Cross-Over Studies | 2 | 2016 | 2029 | 0.060 |
Why?
|
| Kidney Function Tests | 2 | 2007 | 683 | 0.060 |
Why?
|
| Alanine | 1 | 2007 | 572 | 0.060 |
Why?
|
| Mendelian Randomization Analysis | 2 | 2021 | 967 | 0.060 |
Why?
|
| Placebo Effect | 1 | 2009 | 502 | 0.060 |
Why?
|
| Insurance Claim Review | 1 | 2009 | 720 | 0.060 |
Why?
|
| Risk Adjustment | 1 | 2009 | 594 | 0.060 |
Why?
|
| Genetic Testing | 2 | 2009 | 3444 | 0.060 |
Why?
|
| Child, Preschool | 9 | 2022 | 41005 | 0.060 |
Why?
|
| Diabetes Mellitus | 5 | 2013 | 5749 | 0.060 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2010 | 2016 | 0.060 |
Why?
|
| Early Diagnosis | 1 | 2009 | 1184 | 0.060 |
Why?
|
| Mental Health | 1 | 2018 | 3010 | 0.060 |
Why?
|
| Macular Degeneration | 1 | 2012 | 980 | 0.060 |
Why?
|
| Cataract | 1 | 2010 | 834 | 0.060 |
Why?
|
| Insurance, Health | 2 | 2014 | 2494 | 0.060 |
Why?
|
| Analgesics, Opioid | 2 | 2018 | 3677 | 0.060 |
Why?
|
| Pharmacoepidemiology | 1 | 2007 | 323 | 0.060 |
Why?
|
| Synovial Membrane | 1 | 2007 | 507 | 0.060 |
Why?
|
| Health Services | 1 | 2009 | 758 | 0.060 |
Why?
|
| Dopamine Agonists | 1 | 2007 | 355 | 0.060 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2010 | 783 | 0.060 |
Why?
|
| Interviews as Topic | 2 | 2010 | 2539 | 0.060 |
Why?
|
| Drainage | 1 | 2010 | 1142 | 0.060 |
Why?
|
| Disability Evaluation | 3 | 2016 | 1828 | 0.060 |
Why?
|
| Glycine | 1 | 2007 | 671 | 0.060 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2007 | 546 | 0.060 |
Why?
|
| Hospitalists | 1 | 2008 | 305 | 0.060 |
Why?
|
| Tropical Climate | 1 | 2023 | 37 | 0.060 |
Why?
|
| Electric Countershock | 2 | 2018 | 534 | 0.060 |
Why?
|
| China | 1 | 2010 | 2245 | 0.060 |
Why?
|
| Poverty | 1 | 2015 | 2660 | 0.060 |
Why?
|
| Blood Pressure Determination | 1 | 2007 | 633 | 0.060 |
Why?
|
| Cyclooxygenase 2 | 1 | 2006 | 612 | 0.060 |
Why?
|
| Primary Prevention | 1 | 2011 | 1167 | 0.060 |
Why?
|
| Penile Erection | 1 | 2023 | 97 | 0.060 |
Why?
|
| Inflammation Mediators | 1 | 2012 | 1888 | 0.060 |
Why?
|
| Platelet Aggregation Inhibitors | 3 | 2013 | 3070 | 0.060 |
Why?
|
| Internationality | 1 | 2009 | 1002 | 0.060 |
Why?
|
| Triazoles | 1 | 2009 | 908 | 0.060 |
Why?
|
| Secondary Prevention | 1 | 2009 | 1530 | 0.060 |
Why?
|
| Neoplasm Staging | 4 | 2011 | 11031 | 0.060 |
Why?
|
| Viral Load | 2 | 2023 | 3300 | 0.050 |
Why?
|
| Colombia | 1 | 2023 | 258 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2018 | 10943 | 0.050 |
Why?
|
| Osteoarthritis | 1 | 2010 | 1036 | 0.050 |
Why?
|
| Gene Expression | 1 | 2016 | 7798 | 0.050 |
Why?
|
| Antifungal Agents | 1 | 2007 | 729 | 0.050 |
Why?
|
| Interleukin-6 | 2 | 2010 | 3203 | 0.050 |
Why?
|
| Humidity | 1 | 2023 | 197 | 0.050 |
Why?
|
| Walking | 1 | 2010 | 1180 | 0.050 |
Why?
|
| Adipocytes | 1 | 2009 | 1185 | 0.050 |
Why?
|
| Mobile Health Units | 1 | 2023 | 80 | 0.050 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2010 | 1381 | 0.050 |
Why?
|
| Herpesvirus 3, Human | 1 | 2023 | 204 | 0.050 |
Why?
|
| Cholinesterase Inhibitors | 2 | 2015 | 238 | 0.050 |
Why?
|
| Health Care Surveys | 1 | 2009 | 2453 | 0.050 |
Why?
|
| Mexico | 2 | 2014 | 689 | 0.050 |
Why?
|
| Drug Costs | 1 | 2009 | 1105 | 0.050 |
Why?
|
| Survival Rate | 4 | 2012 | 12788 | 0.050 |
Why?
|
| Homeodomain Proteins | 1 | 2011 | 2418 | 0.050 |
Why?
|
| Drug Interactions | 1 | 2006 | 1460 | 0.050 |
Why?
|
| Vaccines, Conjugate | 1 | 2023 | 333 | 0.050 |
Why?
|
| Cost of Illness | 1 | 2011 | 1860 | 0.050 |
Why?
|
| Fibrinopeptide A | 1 | 2021 | 44 | 0.050 |
Why?
|
| Analysis of Variance | 2 | 2009 | 6366 | 0.050 |
Why?
|
| Preventive Health Services | 1 | 2006 | 575 | 0.050 |
Why?
|
| Quinazolines | 1 | 2008 | 1356 | 0.050 |
Why?
|
| Infant | 7 | 2023 | 35134 | 0.050 |
Why?
|
| Factor XI | 1 | 2021 | 26 | 0.050 |
Why?
|
| Models, Genetic | 1 | 2011 | 3493 | 0.050 |
Why?
|
| Hospital Costs | 2 | 2018 | 985 | 0.050 |
Why?
|
| Depressive Disorder, Major | 1 | 2018 | 4639 | 0.050 |
Why?
|
| Prothrombin Time | 1 | 2021 | 119 | 0.050 |
Why?
|
| Polysomnography | 2 | 2018 | 1776 | 0.050 |
Why?
|
| Mutation, Missense | 1 | 2010 | 2566 | 0.050 |
Why?
|
| Factor VII | 1 | 2021 | 139 | 0.050 |
Why?
|
| Ovarian Neoplasms | 1 | 2017 | 4839 | 0.050 |
Why?
|
| Membrane Proteins | 2 | 2009 | 7882 | 0.050 |
Why?
|
| Lung Diseases | 1 | 2011 | 1887 | 0.050 |
Why?
|
| Receptors, Adrenergic, alpha-2 | 1 | 2020 | 64 | 0.050 |
Why?
|
| Linear Models | 2 | 2010 | 5953 | 0.050 |
Why?
|
| Partial Thromboplastin Time | 1 | 2021 | 206 | 0.050 |
Why?
|
| Peripheral Arterial Disease | 1 | 2011 | 1188 | 0.050 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2007 | 1203 | 0.050 |
Why?
|
| Quantitative Trait Loci | 2 | 2022 | 2019 | 0.050 |
Why?
|
| Integrin beta Chains | 1 | 2020 | 121 | 0.050 |
Why?
|
| Likelihood Functions | 1 | 2003 | 1005 | 0.040 |
Why?
|
| Longevity | 1 | 2008 | 1071 | 0.040 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2021 | 281 | 0.040 |
Why?
|
| Sample Size | 1 | 2023 | 845 | 0.040 |
Why?
|
| Cartilage, Articular | 1 | 2007 | 1095 | 0.040 |
Why?
|
| Electronics | 1 | 2021 | 322 | 0.040 |
Why?
|
| Homeostasis | 1 | 2010 | 3339 | 0.040 |
Why?
|
| Pneumococcal Vaccines | 1 | 2023 | 391 | 0.040 |
Why?
|
| Clinical Protocols | 2 | 2016 | 1461 | 0.040 |
Why?
|
| Hypersensitivity | 1 | 2008 | 1102 | 0.040 |
Why?
|
| International Normalized Ratio | 1 | 2021 | 367 | 0.040 |
Why?
|
| Molecular Sequence Annotation | 1 | 2022 | 528 | 0.040 |
Why?
|
| Denmark | 1 | 2021 | 738 | 0.040 |
Why?
|
| Prostatectomy | 2 | 2023 | 1890 | 0.040 |
Why?
|
| Renal Insufficiency | 1 | 2005 | 804 | 0.040 |
Why?
|
| Recurrence | 4 | 2020 | 8340 | 0.040 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2021 | 426 | 0.040 |
Why?
|
| Desogestrel | 1 | 2018 | 23 | 0.040 |
Why?
|
| Hospitals, Rural | 1 | 2020 | 172 | 0.040 |
Why?
|
| Reference Values | 3 | 2013 | 4982 | 0.040 |
Why?
|
| Factor VIII | 1 | 2021 | 347 | 0.040 |
Why?
|
| Hyponatremia | 1 | 2021 | 298 | 0.040 |
Why?
|
| Neurologic Examination | 1 | 2021 | 931 | 0.040 |
Why?
|
| Superior Sagittal Sinus | 1 | 2017 | 17 | 0.040 |
Why?
|
| Quarantine | 1 | 2020 | 170 | 0.040 |
Why?
|
| Vasoconstrictor Agents | 1 | 2021 | 642 | 0.040 |
Why?
|
| Animals | 8 | 2016 | 168768 | 0.040 |
Why?
|
| Kidney Failure, Chronic | 2 | 2008 | 2535 | 0.040 |
Why?
|
| Streptococcus pneumoniae | 1 | 2023 | 714 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2011 | 7785 | 0.040 |
Why?
|
| Brain Injuries | 1 | 2010 | 2029 | 0.040 |
Why?
|
| Attitude to Health | 1 | 2007 | 2052 | 0.040 |
Why?
|
| Coronary Artery Disease | 1 | 2017 | 6486 | 0.040 |
Why?
|
| Fibrinogen | 1 | 2021 | 894 | 0.040 |
Why?
|
| Seasons | 1 | 2023 | 1493 | 0.040 |
Why?
|
| Adipose Tissue | 1 | 2009 | 3280 | 0.040 |
Why?
|
| Peptides | 1 | 2009 | 4410 | 0.040 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 2 | 2010 | 424 | 0.040 |
Why?
|
| von Willebrand Factor | 1 | 2021 | 669 | 0.040 |
Why?
|
| Microarray Analysis | 2 | 2011 | 767 | 0.040 |
Why?
|
| Exhalation | 1 | 2018 | 167 | 0.040 |
Why?
|
| Cortical Spreading Depression | 2 | 2011 | 276 | 0.040 |
Why?
|
| Social Support | 1 | 2006 | 2118 | 0.040 |
Why?
|
| Calcitonin Gene-Related Peptide | 1 | 2019 | 306 | 0.040 |
Why?
|
| Uncertainty | 1 | 2021 | 735 | 0.040 |
Why?
|
| Lipoproteins | 1 | 2021 | 878 | 0.040 |
Why?
|
| Nurses | 2 | 2017 | 2462 | 0.040 |
Why?
|
| Sweden | 1 | 2019 | 1341 | 0.030 |
Why?
|
| Public Opinion | 1 | 2020 | 477 | 0.030 |
Why?
|
| Carrier Proteins | 1 | 2010 | 5023 | 0.030 |
Why?
|
| Perioperative Period | 1 | 2018 | 256 | 0.030 |
Why?
|
| Austria | 1 | 2016 | 202 | 0.030 |
Why?
|
| Intraoperative Period | 1 | 2017 | 520 | 0.030 |
Why?
|
| Emergencies | 1 | 2022 | 1170 | 0.030 |
Why?
|
| Drug Combinations | 2 | 2012 | 1958 | 0.030 |
Why?
|
| Boston | 1 | 2009 | 9312 | 0.030 |
Why?
|
| Workplace | 1 | 2022 | 836 | 0.030 |
Why?
|
| Netherlands | 1 | 2020 | 2170 | 0.030 |
Why?
|
| Software | 1 | 2009 | 4441 | 0.030 |
Why?
|
| India | 1 | 2021 | 2197 | 0.030 |
Why?
|
| Telomerase | 1 | 2020 | 730 | 0.030 |
Why?
|
| Mutation | 2 | 2011 | 29786 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2023 | 2307 | 0.030 |
Why?
|
| Insulin | 1 | 2010 | 6582 | 0.030 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2018 | 544 | 0.030 |
Why?
|
| Nuclear Proteins | 1 | 2010 | 5856 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2017 | 550 | 0.030 |
Why?
|
| Contraception | 1 | 2018 | 359 | 0.030 |
Why?
|
| Spirometry | 1 | 2018 | 865 | 0.030 |
Why?
|
| Quebec | 1 | 2014 | 134 | 0.030 |
Why?
|
| Sensation Disorders | 1 | 2015 | 156 | 0.030 |
Why?
|
| Atlases as Topic | 1 | 2016 | 236 | 0.030 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 2015 | 177 | 0.030 |
Why?
|
| Central Nervous System | 1 | 2022 | 1357 | 0.030 |
Why?
|
| Cardiovascular System | 1 | 2022 | 831 | 0.030 |
Why?
|
| Anti-Retroviral Agents | 1 | 2024 | 1714 | 0.030 |
Why?
|
| Haplotypes | 2 | 2012 | 2779 | 0.030 |
Why?
|
| Arterial Occlusive Diseases | 1 | 1998 | 793 | 0.030 |
Why?
|
| Aphasia | 1 | 2015 | 184 | 0.030 |
Why?
|
| Acute Disease | 2 | 2020 | 7147 | 0.030 |
Why?
|
| Arteriosclerosis | 1 | 1998 | 1092 | 0.030 |
Why?
|
| Pharmaceutical Preparations | 1 | 2022 | 1070 | 0.030 |
Why?
|
| Social Behavior | 1 | 2020 | 1127 | 0.030 |
Why?
|
| Anthropometry | 1 | 2018 | 1350 | 0.030 |
Why?
|
| Models, Biological | 1 | 2010 | 9584 | 0.030 |
Why?
|
| Atrial Fibrillation | 1 | 2011 | 5035 | 0.030 |
Why?
|
| Melanesia | 1 | 2012 | 18 | 0.030 |
Why?
|
| Hyperglycemia | 1 | 2021 | 1373 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2016 | 1590 | 0.030 |
Why?
|
| Blood Chemical Analysis | 1 | 2014 | 440 | 0.030 |
Why?
|
| Norepinephrine | 1 | 2015 | 909 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2008 | 4687 | 0.030 |
Why?
|
| Health Services for the Aged | 1 | 2015 | 269 | 0.030 |
Why?
|
| Visual Acuity | 2 | 2012 | 2530 | 0.030 |
Why?
|
| Thrombosis | 1 | 2006 | 2968 | 0.030 |
Why?
|
| Disease Outbreaks | 1 | 2021 | 1771 | 0.030 |
Why?
|
| Infant, Newborn | 4 | 2016 | 25628 | 0.030 |
Why?
|
| Muscle, Smooth | 1 | 2016 | 934 | 0.030 |
Why?
|
| Reference Standards | 1 | 2016 | 1025 | 0.030 |
Why?
|
| Pain Threshold | 1 | 2016 | 584 | 0.030 |
Why?
|
| Calcium Channels, N-Type | 1 | 2011 | 39 | 0.030 |
Why?
|
| Anesthetics | 1 | 2018 | 539 | 0.030 |
Why?
|
| Genes, X-Linked | 1 | 2012 | 128 | 0.030 |
Why?
|
| Hyperalgesia | 1 | 2016 | 502 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2021 | 5077 | 0.030 |
Why?
|
| Health Personnel | 1 | 2005 | 3219 | 0.020 |
Why?
|
| International Cooperation | 1 | 2018 | 1420 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2015 | 1655 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 2009 | 6364 | 0.020 |
Why?
|
| Injury Severity Score | 1 | 2014 | 1014 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2007 | 9445 | 0.020 |
Why?
|
| Retreatment | 1 | 2012 | 610 | 0.020 |
Why?
|
| Wakefulness | 1 | 2018 | 1245 | 0.020 |
Why?
|
| Premenopause | 1 | 2014 | 1033 | 0.020 |
Why?
|
| Antibodies, Viral | 1 | 2021 | 3177 | 0.020 |
Why?
|
| Pharmacogenetics | 1 | 2014 | 674 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2006 | 5135 | 0.020 |
Why?
|
| Radioimmunoassay | 1 | 2010 | 919 | 0.020 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2008 | 5223 | 0.020 |
Why?
|
| Signal Transduction | 2 | 2009 | 23404 | 0.020 |
Why?
|
| Nursing Homes | 1 | 2016 | 1036 | 0.020 |
Why?
|
| Interleukin-9 | 1 | 2009 | 63 | 0.020 |
Why?
|
| Population Groups | 1 | 2010 | 209 | 0.020 |
Why?
|
| Geriatric Assessment | 1 | 2016 | 1372 | 0.020 |
Why?
|
| Intraoperative Complications | 1 | 2016 | 1198 | 0.020 |
Why?
|
| Melanoma | 1 | 2007 | 5511 | 0.020 |
Why?
|
| Withholding Treatment | 1 | 2013 | 599 | 0.020 |
Why?
|
| Musculoskeletal System | 1 | 2010 | 175 | 0.020 |
Why?
|
| Receptors, CCR2 | 1 | 2009 | 212 | 0.020 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2018 | 6036 | 0.020 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2010 | 504 | 0.020 |
Why?
|
| Pregnancy | 1 | 2010 | 29144 | 0.020 |
Why?
|
| Pulse Therapy, Drug | 1 | 2007 | 35 | 0.020 |
Why?
|
| British Columbia | 1 | 2008 | 244 | 0.020 |
Why?
|
| Internship and Residency | 1 | 2008 | 5791 | 0.020 |
Why?
|
| Genetic Variation | 2 | 2018 | 6542 | 0.020 |
Why?
|
| Combined Modality Therapy | 2 | 2016 | 8642 | 0.020 |
Why?
|
| Collagen Type X | 1 | 2007 | 16 | 0.020 |
Why?
|
| Collagen Type XI | 1 | 2007 | 20 | 0.020 |
Why?
|
| Observer Variation | 2 | 2005 | 2593 | 0.020 |
Why?
|
| Collagen Type IX | 1 | 2007 | 20 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2009 | 644 | 0.020 |
Why?
|
| Itraconazole | 1 | 2007 | 43 | 0.020 |
Why?
|
| Receptor, Serotonin, 5-HT1D | 1 | 2007 | 9 | 0.020 |
Why?
|
| ROC Curve | 1 | 2015 | 3528 | 0.020 |
Why?
|
| Control Groups | 1 | 2007 | 105 | 0.020 |
Why?
|
| Receptor, Serotonin, 5-HT1B | 1 | 2007 | 33 | 0.020 |
Why?
|
| Aggrecans | 1 | 2007 | 90 | 0.020 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2008 | 216 | 0.020 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2011 | 1159 | 0.020 |
Why?
|
| Fluconazole | 1 | 2007 | 146 | 0.020 |
Why?
|
| Regenerative Medicine | 1 | 2010 | 307 | 0.020 |
Why?
|
| Collagen Type II | 1 | 2007 | 151 | 0.020 |
Why?
|
| Cartilage | 1 | 2010 | 818 | 0.020 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2015 | 3255 | 0.020 |
Why?
|
| Naphthalenes | 1 | 2007 | 194 | 0.020 |
Why?
|
| Transaminases | 1 | 2007 | 200 | 0.020 |
Why?
|
| Stem Cells | 2 | 2010 | 3567 | 0.020 |
Why?
|
| Ki-67 Antigen | 1 | 2009 | 644 | 0.020 |
Why?
|
| Frontal Lobe | 1 | 2013 | 1406 | 0.020 |
Why?
|
| SOX9 Transcription Factor | 1 | 2007 | 146 | 0.020 |
Why?
|
| High Mobility Group Proteins | 1 | 2007 | 187 | 0.020 |
Why?
|
| Incidental Findings | 1 | 2011 | 689 | 0.020 |
Why?
|
| Endothelium | 1 | 2009 | 778 | 0.020 |
Why?
|
| Cystatin C | 1 | 2007 | 250 | 0.020 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2008 | 563 | 0.020 |
Why?
|
| Health Services Needs and Demand | 1 | 2014 | 1410 | 0.020 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2009 | 689 | 0.020 |
Why?
|
| Emergency Medical Services | 1 | 2018 | 1917 | 0.020 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2009 | 610 | 0.020 |
Why?
|
| Cataract Extraction | 1 | 2010 | 481 | 0.020 |
Why?
|
| Serine | 1 | 2010 | 826 | 0.020 |
Why?
|
| Cerebellum | 1 | 2013 | 1488 | 0.020 |
Why?
|
| Liver Function Tests | 1 | 2007 | 528 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2010 | 1252 | 0.020 |
Why?
|
| Self Medication | 1 | 2006 | 117 | 0.020 |
Why?
|
| Acute Kidney Injury | 1 | 2018 | 1968 | 0.020 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2014 | 1004 | 0.020 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2008 | 629 | 0.020 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2009 | 644 | 0.020 |
Why?
|
| Linkage Disequilibrium | 1 | 2010 | 1997 | 0.020 |
Why?
|
| Proteins | 1 | 2020 | 6100 | 0.020 |
Why?
|
| Health Care Reform | 1 | 2014 | 1261 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2008 | 13693 | 0.020 |
Why?
|
| Alcoholic Beverages | 1 | 2006 | 265 | 0.020 |
Why?
|
| Disease Susceptibility | 1 | 2011 | 1782 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2022 | 9274 | 0.020 |
Why?
|
| Pedigree | 1 | 2012 | 4642 | 0.020 |
Why?
|
| Selection Bias | 1 | 2006 | 371 | 0.010 |
Why?
|
| Collagen Type I | 1 | 2007 | 592 | 0.010 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2008 | 841 | 0.010 |
Why?
|
| Fasting | 1 | 2010 | 1592 | 0.010 |
Why?
|
| Heart Failure | 1 | 2007 | 10895 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2008 | 13104 | 0.010 |
Why?
|
| Edetic Acid | 1 | 2003 | 275 | 0.010 |
Why?
|
| Anxiety Disorders | 1 | 2014 | 2690 | 0.010 |
Why?
|
| Diabetic Angiopathies | 1 | 2008 | 818 | 0.010 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2008 | 1142 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 3873 | 0.010 |
Why?
|
| Chondrocytes | 1 | 2007 | 804 | 0.010 |
Why?
|
| Sleep | 1 | 2018 | 4622 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2010 | 3921 | 0.010 |
Why?
|
| Demography | 1 | 2006 | 1655 | 0.010 |
Why?
|
| Telephone | 1 | 2005 | 617 | 0.010 |
Why?
|
| Depressive Disorder | 1 | 2014 | 3747 | 0.010 |
Why?
|
| Prostate-Specific Antigen | 1 | 2011 | 2494 | 0.010 |
Why?
|
| Cattle | 1 | 2007 | 3922 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2009 | 3616 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2007 | 3508 | 0.010 |
Why?
|
| Computational Biology | 1 | 2013 | 3519 | 0.010 |
Why?
|
| Psychometrics | 1 | 2010 | 3003 | 0.010 |
Why?
|
| Multiple Sclerosis | 1 | 2015 | 3079 | 0.010 |
Why?
|
| Base Sequence | 1 | 2012 | 12797 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2011 | 4851 | 0.010 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2007 | 1516 | 0.010 |
Why?
|
| Genomics | 1 | 2016 | 5717 | 0.010 |
Why?
|
| Heterozygote | 1 | 2007 | 2804 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2015 | 12961 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2007 | 3914 | 0.010 |
Why?
|
| Lipoproteins, HDL | 1 | 2003 | 638 | 0.010 |
Why?
|
| Smoking Cessation | 1 | 2011 | 2071 | 0.010 |
Why?
|
| Lung | 1 | 2018 | 9857 | 0.010 |
Why?
|
| Prostate | 1 | 2007 | 1775 | 0.010 |
Why?
|
| Transcription Factors | 2 | 2010 | 12207 | 0.010 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2008 | 2938 | 0.010 |
Why?
|
| Health Expenditures | 1 | 2011 | 2349 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2010 | 8436 | 0.010 |
Why?
|
| Autoimmune Diseases | 1 | 2010 | 2134 | 0.010 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2006 | 1872 | 0.010 |
Why?
|
| Academic Medical Centers | 1 | 2008 | 2760 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2007 | 6489 | 0.010 |
Why?
|
| Muscle, Skeletal | 1 | 2012 | 4925 | 0.010 |
Why?
|
| Biopsy | 1 | 2009 | 6755 | 0.010 |
Why?
|
| Bone Neoplasms | 1 | 2009 | 2530 | 0.010 |
Why?
|
| Quality Assurance, Health Care | 1 | 2007 | 2212 | 0.010 |
Why?
|
| Body Weight | 1 | 2007 | 4671 | 0.010 |
Why?
|
| Weight Loss | 1 | 2007 | 2625 | 0.010 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2007 | 3617 | 0.010 |
Why?
|
| Language | 1 | 2005 | 1471 | 0.010 |
Why?
|
| Cell Line | 1 | 2010 | 16000 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2010 | 5172 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2009 | 11366 | 0.010 |
Why?
|
| Lipid Metabolism | 1 | 2003 | 1889 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2007 | 8319 | 0.010 |
Why?
|
| Endarterectomy, Carotid | 1 | 1999 | 546 | 0.010 |
Why?
|
| Mice | 2 | 2011 | 81201 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 2006 | 4153 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2010 | 11486 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2009 | 7914 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2011 | 9240 | 0.010 |
Why?
|
| Apoptosis | 1 | 2009 | 9724 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2007 | 13035 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2010 | 21833 | 0.010 |
Why?
|
| Anticoagulants | 1 | 1999 | 4600 | 0.000 |
Why?
|